Keyword search (3,171 papers available)


Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Author(s): Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Trembla...

Can J Cardiol. 2016 05;32(5):569-88 Authors: Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean...

Article GUID: 27118291
Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Author(s): Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cli...

Can J Cardiol. 2017 05;33(5):557-576 Authors: Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Mil...

Article GUID: 28449828
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Author(s): Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, B...

Can J Cardiol. 2018 05;34(5):506-525 Authors: Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tr...

Article GUID: 29731013
Title:Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.
Authors:Nerenberg KA,  Zarnke KB,  Leung AA,  Dasgupta K,  Butalia S,  McBrien K,  Harris KC,  Nakhla M,  Cloutier L,  Gelfer M,  Lamarre-Cliche M,  Milot A,  Bolli P,  Tremblay G,  McLean D,  Padwal RS,  Tran KC,  Grover S,  Rabkin SW,  Moe GW,  Howlett JG,  Lindsay P,  Hill MD,  Sharma M,  Field T,  Wein TH,  Shoamanesh A,  Dresser GK,  Hamet P,  Herman RJ,  Burgess E,  Gryn SE,  Grégoire JC,  Lewanczuk R,  Poirier L,  Campbell TS,  Feldman RD,  Lavoie KL,  Tsuyuki RT,  Honos G,  Prebtani APH,  Kline G,  Schiffrin EL,  Don-Wauchope A,  Tobe SW,  Gilbert RE, 
Link:https://www.ncbi.nlm.nih.gov/pubmed/29731013?dopt=Abstract
Category:Can J Cardiol
PMID:29731013
Dept Affiliation: NA
1 Division of General Internal Medicine, Departments of Medicine, Obstetrics and Gynecology, Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. Electronic address: kara.nerenberg@ucalgary.ca.
2 O'Brien Institute for Public Health and Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
3 Division of Endocrinology and Metabolism, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
4 Department of Medicine and Centre for Outcomes Research and Evaluation, McGill University and Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
5 Departments of Medicine and Community Health Sciences, O'Brien Institute for Public Health and Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada.
6 Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
7 Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
8 Department of Nursing, Université du Québec à Trois-Rivières, Trois-Rivières, Quebec, Canada.
9 Department of Family Practice, University of British Columbia, Vancouver, British Columbia, Canada.
10 Université de Montréal, Montréal, Quebec, Canada.
11 Department of Medicine, Université Laval, Québec, Quebec, Canada.
12 McMaster University, Hamilton, Ontario, Canada.
13 CHU-Québec-Hopital St. Sacrement, Québec, Quebec, Canada.
14 Alberta Health Services and Covenant Health, Edmonton, Alberta, Canada.
15 Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
16 Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
17 McGill Comprehensive Health Improvement Program (CHIP), Montreal, Quebec, Canada.
18 Vancouver Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
19 St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
20 Departments of Medicine and Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada.
21 Director of Stroke, Heart and Stroke Foundation of Canada, Adjunct Faculty, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
22 Department of Clinical Neurosciences, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
23 McMaster University, Hamilton Health Sciences, Population Health Research Institute, Hamilton, Ontario, Canada.
24 University of British Columbia, Vancouver Stroke Program, Vancouver, British Columbia, Canada.
25 McGill University, Stroke Prevention Clinic, Montreal General Hospital, Montreal, Quebec, Canada.
26 Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
27 Faculté de Médicine, Université de Montréal, Montréal, Quebec, Canada.
28 Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
29 Department of Medicine, Western University, London, Ontario, Canada.
30 Université de Montréal, Institut de cardiologie de Montréal, Montréal, Quebec, Canada.
31 Institut National d'Excellence en Sante et Services Sociaux, Québec, Quebec, Canada.
32 Department of Psychology, University of Calgary, Calgary, Alberta, Canada. <

Description:

Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.

Can J Cardiol. 2018 05;34(5):506-525

Authors: Nerenberg KA, Zarnke KB, Leung AA, Dasgupta K, Butalia S, McBrien K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Padwal RS, Tran KC, Grover S, Rabkin SW, Moe GW, Howlett JG, Lindsay P, Hill MD, Sharma M, Field T, Wein TH, Shoamanesh A, Dresser GK, Hamet P, Herman RJ, Burgess E, Gryn SE, Grégoire JC, Lewanczuk R, Poirier L, Campbell TS, Feldman RD, Lavoie KL, Tsuyuki RT, Honos G, Prebtani APH, Kline G, Schiffrin EL, Don-Wauchope A, Tobe SW, Gilbert RE, Leiter LA, Jones C, Woo V, Hegele RA, Selby P, Pipe A, McFarlane PA, Oh P, Gupta M, Bacon SL, Kaczorowski J, Trudeau L, Campbell NRC, Hiremath S, Roerecke M, Arcand J, Ruzicka M, Prasad GVR, Vallée M, Edwards C, Sivapalan P, Penner SB, Fournier A, Benoit G, Feber J, Dionne J, Magee LA, Logan AG, Côté AM, Rey E, Firoz T, Kuyper LM, Gabor JY, Townsend RR, Rabi DM, Daskalopoulou SS, Hypertension Canada

Abstract

Hypertension Canada provides annually updated, evidence-based guidelines for the diagnosis, assessment, prevention, and treatment of hypertension in adults and children. This year, the adult and pediatric guidelines are combined in one document. The new 2018 pregnancy-specific hypertension guidelines are published separately. For 2018, 5 new guidelines are introduced, and 1 existing guideline on the blood pressure thresholds and targets in the setting of thrombolysis for acute ischemic stroke is revised. The use of validated wrist devices for the estimation of blood pressure in individuals with large arm circumference is now included. Guidance is provided for the follow-up measurements of blood pressure, with the use of standardized methods and electronic (oscillometric) upper arm devices in individuals with hypertension, and either ambulatory blood pressure monitoring or home blood pressure monitoring in individuals with white coat effect. We specify that all individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure. Finally, an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in individuals with heart failure (with ejection fraction < 40%) who are symptomatic despite appropriate doses of guideline-directed heart failure therapies. The specific evidence and rationale underlying each of these guidelines are discussed.

PMID: 29731013 [PubMed - indexed for MEDLINE]